Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-sirolimus (ABI-009) in Recurrent High-Grade Glioma and Newly Diagnosed Glioblastoma
NCT03463265Phase 2Completed
- Sponsor
- Aadi Bioscience, Inc.
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus in high-grade glioma (HGG), glioblastoma (GBM), sponsored by Aadi Bioscience, Inc.. Started Aug 2018; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
high-grade glioma (HGG)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03463265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463265.